ViroGates FY2025 annual report published; net revenue rises to DKK 5 million

ViroGates reported continued execution of its strategy to expand suPARnostic beyond acute care and research into preventive health and longevity-focused testing.
Management said it worked with its US distribution partner suPARbio on laboratory onboarding and logistics in preparation for a broader US launch.
The company said FDA feedback indicated suPARnostic TurbiLatex would require a de novo submission for US market entry.
A proof of concept for an updated suPARnostic POC+ was reached with GENSPEED Biotech, with launch preparations targeted for late 2026.
ViroGates said it completed a directed capital raise of about DKK 19.3 million and ended the year with DKK 26.3 million in cash and cash equivalents.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ViroGates A/S published the original content used to generate this news brief on March 26, 2026, and is solely responsible for the information contained therein.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.